Veracyte, Inc.
VCYT
$28.61
-$0.46-1.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.91% | 23.42% | 23.46% | 23.95% | 21.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.91% | 23.42% | 23.46% | 23.95% | 21.59% |
| Cost of Revenue | 15.61% | 15.96% | 8.27% | 4.26% | 0.43% |
| Gross Profit | 21.80% | 26.84% | 31.57% | 34.97% | 34.00% |
| SG&A Expenses | 8.29% | 8.92% | 8.60% | 11.66% | 5.91% |
| Depreciation & Amortization | -19.85% | -23.77% | -27.81% | -25.71% | -17.99% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.58% | 10.80% | 12.04% | 14.45% | 10.36% |
| Operating Income | 3,935.97% | 369.35% | 219.55% | 151.36% | 103.23% |
| Income Before Tax | 152.87% | 149.81% | 133.60% | 83.52% | -91.02% |
| Income Tax Expenses | 451.20% | 190.19% | 172.74% | 193.32% | -299.47% |
| Earnings from Continuing Operations | 148.73% | 148.48% | 132.44% | 81.45% | -85.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 148.73% | 148.48% | 132.44% | 81.45% | -85.96% |
| EBIT | 3,935.97% | 369.35% | 219.55% | 151.36% | 103.23% |
| EBITDA | 151.17% | 316.27% | 377.45% | 333.48% | 528.19% |
| EPS Basic | 145.78% | 145.78% | 130.60% | 79.63% | -84.47% |
| Normalized Basic EPS | 308.48% | 1,536.36% | 433.42% | 276.66% | 147.40% |
| EPS Diluted | 143.73% | 143.67% | 128.80% | 78.16% | -84.61% |
| Normalized Diluted EPS | 304.35% | 1,507.91% | 427.16% | 274.11% | 147.19% |
| Average Basic Shares Outstanding | 4.65% | 5.47% | 5.28% | 4.19% | 3.15% |
| Average Diluted Shares Outstanding | 6.37% | 7.65% | 6.79% | 4.91% | 3.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |